News

01.02.24 Sir Graham Brady MP appointed to the board of Medannex
18.01.24 Nature publication demonstrates anti-cancer effects of MDX-124 in multiple tumour types
20.09.23 FDA Grants US Orphan Drug Designation to Medannex’s First-in-Class Therapy MDX-124
21.08.23 Medannex Announces First Patient Treated in Phase 1b Clinical Study of Groundbreaking Anti-Annexin-A1 Therapy
24.04.23 Medannex’s First-in-class Therapy Awarded UK ‘Innovation Passport’ to Accelerate Time to Market
01.03.23 MDX-124 receives Orphan Designation from the EMA for the Treatment of Pancreatic Cancer
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. 6
  8. 7